Introduction
============

Guidelines for assessing the quality of active pharmaceutical ingredient (API) and medicinal products has been developed by ICH, FDA, WHO or EMA, which are focused to the greatest extent, firstly to verify the stability of the API through the establishment of various tests and the way there are conducted ([@B14]). Secondly, the confirmation of the presence of impurities is performed ([@B16]). Studies are performed to explore various paths of the potential degradation of the API, evaluating the rate of changes under the influence of various factors.

For a comprehensive evaluation process associated with the pharmaceutical stability, there is a need to perform various tests, which results should be the answer whether the drug substance is stable. The most important for the drug substance are so-called stress tests, which involve overly intense exposure to factors such as: strong acid, base, hydrogen peroxide, high temperature or light, in a manner individual to the different drugs ([@B15]; [@B28]). When the chemical stability of APIs is considered, the effects of chemical reactions of the API are evaluated, mainly: hydrolysis in conditions of increased humidity, oxidation in the presence of oxygen or hydrogen peroxide, isomerization, hydration, dimerization, or decarboxylation. Photostability tests are characterized by particular specificity and are an integral part of stability tests that are included in standard, [@B14]. It is worth noting that the concept of photodegradation is related not only to changes in the structure of the API under the influence of light, but also to the occurrence of free-radical processes, energy transfer, or even luminescence, which may lead to unexpected and atypical results, especially in the solid state ([@B12]). There is a special need to recognize all possibilities of degradation of new pharmaceutical compound especially those, which are not recognized in Pharmacopeia yet.

Determination of unknown impurities in the new drug compound is based on the results obtained during various stress tests, thus during chemical stability evaluation. Identification of degradation products is primarily concentrated on establishing its structure, with simultaneous determination of physicochemical properties, and then toxicity estimation accordingly to the latest recommendations ([@B3]; [@B8]; [@B22]; [@B13]). The first ICH regulations regarding the quantitation limit of impurities in drug, were based solely on a patient daily dose of API, routes of administration and duration of therapy and the identification of impurity of concentration below 0.1% was unrequired ([@B17]). In addition, there was also the lack of awareness of impurities existing in the drug substance itself, but in the finished product mainly. In 2004 there has been a noticeable change in the approach to standards and thresholds of impurities, as a reaction to the proposal developed by the EMEA, in which necessity for determination of the genotoxic impurities limits in the API was stated ([@B8]; [@B21]). It has been proposed that the lowest possible quantitation limit of impurities should be enforced in cases of the predicted presence of a genotoxic substance formed from an API ([@B6]; [@B20]). The latest guidelines has been developed in 2014 and requirement to use at least two forecasting models of mutagenicity predicting *in silico* was established.

According to current recommendations, it is important to provide a lot of results in the area of stability testing research in case of newly implemented pharmaceutical compounds as well as others already known ([@B18]). Ivabradine (**IVA**) is a new drug compound in the treatment of heart failure patients and the only implemented HCN4 channel inhibitor. The drug received an expedited review under the FDA's priority review program and the approval was based on results of the shift trial, published in 2010. Locking HCN4 channel results in slower growth of pacemaker current and as a result reducing the heart rate. Such action is used to treat angina, especially in patients with intolerance to β-blockers. **IVA** is metabolized by cytochrome CYP3A4 and does not affect metabolism and plasma concentration of other cytochome inhibitors. Ivabradine is a highly soluble *S*-enantiomer with no *in vivo* conversion. The only known active metabolite is *N*-desmethyl ivabradine ([@B5]; [@B7]). There are no officially published impurities for **IVA** in pharamacopeias. The only results focused on degradation and *in silico* studies have been performed recently ([@B23]). So that, it is important to provide an independent point of view and new data.

There are many models and approaches of *in silico* studies ([@B25], [@B26]). In this work, Prediction SwissTarget and ePhysChem tools were applied ([@B11]; [@B9]). By using the above-mentioned software, we evaluated the toxicity of some identified degradation products. They were defined by physicochemical parameters such as logP and solubility, which determine the pharmacokinetics. The **IVA** impact on cytochrome P450 (a group of enzymes with oxidase activity responsible among other things for the detoxification of the body) has also been examined ([@B4]). The major enzyme from the group of cytochrome P450 isoenzymes is CYP3A4, responsible for the metabolism of most drugs or xenobiotics. Drugs can be metabolized by different enzymes such as CYP2D6, CYP2C9, CYP2C19, and CYP1A2, therefore, different metabolites are formed, which activity may be similar to the original drug substance. Sometimes these products cause toxic effects ([@B29]; [@B23]).

Physicochemical parameters such as logP and solubility of degradation products are discussed in this work because of their importance in perspective of pharmacokinetics ([@B1]; [@B2]). If the drug is administered orally, as ivabradine, it is exposed to low pH in the stomach, which may form chlorides drug substance with altered properties ([@B2]).

The main object of this work is to conduct a forced degradation of ivabradine and propose its possible degradation products. Stress tests were carried out mainly in context of resistance to the oxidizing agent, light as well as acid and base hydrolysis. Additionally, the calculated physicochemical, pharmacological and toxic properties of possible degradation products were presented.

Materials and Methods {#s1}
=====================

Chemicals
---------

The tested ivabradine hydrochloride (purity ≥ 99%) bulk powder was supplied by Watson International Ltd. (Kunshan, China). Acetonitrile was purchased from Sigma-Aldrich Chemical CO. (St. Louis, MO, USA), ammonium acetate, hydrochloric acid and sodium hydroxide all pure p. a. were purchased from POCH (Gliwice, Poland). 30% Hydrogen peroxide was supplied by J. T. Baker, (Deventer, The Netherlands). Pure water was obtained from Direct-Q3 UV-R Ultrapure water purification system, Merck Millipore (Darmstadt, Germany).

Equipment and Conditions
------------------------

LC-MS/MS analysis was performed with HPLC Agilent 1100 (AgilentTechnologies, Santa Clara, CA, USA) equipment coupled with QSTAR XL (AbSciex, Framingham, MA, USA) mass spectrometer. Electrospray ionization (ESI) was operated in a positive ion mode in order to obtain soft and efficient ionization of ivabradine and its degradation products. Kromasil 100 C8 (4.6 mm × 250 mm, 5 μm, AkzoNobel, Amsterdam, Netherlands) was used in reversed-phase mode with isocratic elution. Mobile phase composition was 65% of component A (20 mM ammonium acetate) and 35% of component B (acetonitrile). Total analysis time was 30 min. Column temperature throughout the analysis was 25°C the flow rate of the mobile phase was 1 ml/min and the injection volume was 20 μl. The high resolution Q-TOF mass spectrometer was operated in SCAN mode to obtain mass spectrum in the mass range 220--1000 m/z. MS/MS mass spectra were obtained by collision-induced dissociation of selected parent ions in Product Ion mode of mass spectrometer. Degradation studies were carried out in Thermostat CC2-K6 made by Huber company (Offenburg, Germany), photo stability studies were performed in a photostability Suntest + Atlas chamber (Accelerated Tabletop Exposure Systems) with xenon lamp. Shimadzu UV-1800 UV-Vis spectrophotometer was also used in the studies.

Stress Testing
--------------

In order to prepare degradation sample, for each of the samples 1mg of ivabradine were weighed and dissolved in 2 ml of the appropriate solvent for particular test sample.

Thermal degradation was performed by adding deionized water and kept for 24 h in 80°C. To achieve an acid and alkaline hydrolysis a 2 M HCl solution and 1 M NaOH were added, respectively, respectively and incubated for 24 h in 80°C. Studies of possible oxidation products were carried out by adding 3% H~2~O~2~, 7.5% H~2~O~2~ and 15% H~2~O~2~ and incubated for 24 h in 80°C. Photolytic degradation was performed in solution of deionized water for 24 and 48 h as well as in solid form for 120 h. The illuminance was set at 500 W/m^2^.

*In Silico* Calculations
------------------------

Ivabradine is metabolized by cytochrome P450. To calculate the probable metabolites, Toxtree program was used ([@B27]), applying SMARTCyp method to predict the fragments in the molecule, which are the most susceptible to activity of cytochrome P450.

For the calculation of toxicity (CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2), logP, solubility and Ames test, [@B9] was used, while the prediction of degradation compounds on potassium/sodium hyper polarization activated cyclic nucleotide-gated channel 4 (HCN4) were counted using SwissTargetPrediction ([@B11]). Calculations were made for **IVA** and compounds **N1**, **Ox1**, **Ox4**, **Ox5**, **UV1,** and **UV2**.

Results and Discussion
======================

Metabolism/Degradation Products Prediction
------------------------------------------

Cytochrome P450 is an enzyme, which demonstrates a monooxygenase activity ([@B29]). In the absence of these enzymes, but with an appropriate amount of supplied energy as heat, redox potential, a strong electrolyte, or UV radiation, reactions can occur *in vitro* to form the same or similar degradation products. Using the structure of the molecule and the Toxtree software ([@B27]), theoretical metabolites which may be produced by the action of cytochrome P450 were calculated (**Figure [1](#F1){ref-type="fig"}**).

![**Theoretical metabolites: main (rank 1) -- **(A--C)** and secondary (rank 3 and \> 4) -- (**D--F**) generated by the usage of software Toxtree**.](fphar-07-00117-g001){#F1}

These theoretical degradation products formed by the *N*-demethylation (**Figures [1A--E](#F1){ref-type="fig"}**) and *N*-oxidation (**Figure [1F](#F1){ref-type="fig"}**) are presented in **Figure [1](#F1){ref-type="fig"}**.

Chromatogram Evaluation
-----------------------

Ivabradine was tested with the addition of HCl and NaOH (**Figures [2A,B](#F2){ref-type="fig"}**), wherein the concentration of used HCl was greater than the concentration of used NaOH. On the chromatogram obtained from a sample after acidic hydrolysis reaction of **IVA** (**Figure [2A](#F2){ref-type="fig"}**) a satisfactory separation of ivabradine and the degradation products is observed. Only compound **H2** was not separated from other neighboring unidentified peak. Separation of the basic hydrolysis degradation products of ivabradine was achieved with satisfactory result (**Figure [2B](#F2){ref-type="fig"}**).

![**Chromatograms obtained by the HPLC separation of products of **(A)** acid hydrolysis and **(B)** alkaline hydrolysis of ivabradine**.](fphar-07-00117-g002){#F2}

Complete degradation of **IVA** was observed in all samples containing hydrogen peroxide (**Figures [3A--C](#F3){ref-type="fig"}**). Chromatographic separation of degradation products was achieved. It was noted, that peaks corresponding to the products **Ox5** and **Ox4** are smaller in case the higher concentration of hydrogen peroxide is used in respective samples.

![**HPLC chromatogram showing effect on the addition of different amounts of H~2~O~2~**(A)** 3%, **(B)** 7.5%, and **(C)** 15%**.](fphar-07-00117-g003){#F3}

During 24 h photodegradation of **IVA**, six degradation products were produced (**Figure [4A](#F4){ref-type="fig"}**). 48-h exposure to UV radiation caused complete decomposition of **IVA** in solution (**Figure [4B](#F4){ref-type="fig"}**) as well as reduction of the intense of peak corresponding to the product **UV2**. Peaks separation in each UV-tested samples were satisfactory. A lot of photoproducts in samples and relatively short time of analysis resulted in insufficient separation of compound **UV1**. Solid powder form of ivabradine, exposed to irradiation for 120 h, was proved to be durable, because any degradation product on the chromatogram was reveled (**Figure [4C](#F4){ref-type="fig"}**).

![**HPLC chromatogram showing photolytic degradation in solution (**A**) for 24 h, **(B)** 48 h, and **(C)** in solid for 120 h**.](fphar-07-00117-g004){#F4}

Determination of degradation products is presented in **Table [1](#T1){ref-type="table"}**. Differences in retention times and distorted shape of the peaks corresponding to ivabradine compound tested in hydrolytic as well as photolytic reaction, is probably caused by the formation of enantiomers during degradation processes.

###### 

Degradation products of all tested samples.

  Sample                      Degradation products           Ivabradine \[min\]
  --------------------------- ------------------------------ --------------------
  Acid decomposition          H1, H2, H3                     12.40
  Alkaline decomposition      N1                             12.20
  Oxidation (3% H~2~O~2~)     Ox1, Ox2, Ox3, Ox4, Ox5        --
  Oxidation (7.5% H~2~O~2~)   Ox1, Ox2, Ox4, Ox5             --
  Oxidation (15% H~2~O~2~)    Ox1, Ox2, Ox5                  --
  Photolysis (24 h)           Ox1, UV, UV2, Ox4, UV3, UV4,   11.60
  Photolysis (48 h)           Ox1, UV2                       --
  Photolysis (powder 120 h)   --                             11.64
                                                             

Degradation Product Identification
----------------------------------

Using the above described apparatus and conditions, MS/MS analyses were performed for all chromatographic peaks ([@B10]; [@B19]).

The resulting MS/MS spectra with the proposed fragmentation patterns are presented in **Figures [5](#F5){ref-type="fig"}--[11](#F11){ref-type="fig"}**. The proposed structures of degradation products together with other experimental data are presented in **Table [2](#T2){ref-type="table"}**. The accuracy of the experimental mass degradation products with the theoretical masses are shown in **Table [3](#T3){ref-type="table"}**.

![**Proposed structure and MS/MS fragmentation pattern of H1.** **(A)** MS spectrum and **(B)** MS/MS spectrum of \[M+H\]^+^ ion at 505.31 *m/z*.](fphar-07-00117-g005){#F5}

![**Proposed structure and MS/MS fragmentation pattern of H2.** **(A)** MS spectrum and **(B)** MS/MS spectrum of \[M+H\]^+^ ion at 523.26 *m/z*.](fphar-07-00117-g006){#F6}

![**Proposed structure and MS/MS fragmentation pattern of H3.** **(A)** MS spectrum and **(B)** MS/MS spectrum of \[M+H\]^+^ ion at 505.25 *m/z*.](fphar-07-00117-g007){#F7}

![**Proposed structure and MS/MS fragmentation pattern of N1.** **(A)** MS spectrum and **(B)** MS/MS spectrum of \[M+H\]^+^ ion at 487.29 *m/z*.](fphar-07-00117-g008){#F8}

![**Proposed structure and MS/MS fragmentation pattern of Ox4.** **(A)** MS spectrum and **(B)** MS/MS spectrum of \[M+H\]^+^ ion at 293.20 *m/z*.](fphar-07-00117-g009){#F9}

![**Proposed structure and MS/MS fragmentation pattern of UV1.** **(A)** MS spectrum and **(B)** MS/MS spectrum of \[M+H\]^+^ ion at 279.17 *m/z*.](fphar-07-00117-g010){#F10}

![**Proposed structure and MS/MS fragmentation pattern of UV4.** **(A)** MS spectrum and **(B)** MS/MS spectrum of \[M+H\]^+^ ion at 455.26 *m/z*.](fphar-07-00117-g011){#F11}

###### 

Comparison of structural formulas, chemical formulas, retention times, molecular ions, as well as the fragment ions of the products obtained in the experiment.

  No               Structural formula             Chemical formula                                                 Retention time \[min\]                                                                           \[M+H\]^+^   Fragment ions^a^
  ---------------- ------------------------------ ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------ ------------------------------
  **Hydrolysis**                                                                                                                                                                                                                 
  H1               ![](fphar-07-00117-i001.jpg)   C~27~H~40~ClN~2~O~7~                                             HCl -- 5.28                                                                                      505          151, 177, 206, 223, 266, 280
  H2               ![](fphar-07-00117-i002.jpg)   C~27~H~39~ClN~2~O~6~                                             HCl -- 6.92                                                                                      523          177, 206, 213, 223, 280, 284
  H3               ![](fphar-07-00117-i003.jpg)   C~27~H~37~ClN~2~O~5~                                             HCl -- 9.45                                                                                      505          206, 262
  N1               ![](fphar-07-00117-i004.jpg)   C~27~H~38~N~2~O~6~                                               NaOH -- 8.11                                                                                     487          177, 280
  **Oxidation**                                                                                                                                                                                                                  
  Ox1              ![](fphar-07-00117-i005.jpg)   C~15~H~21~N~2~O~4~                                               3% H~2~O~2~ -- 2.40 7.5% H~2~O~2~ -- 2.40 15% H~2~O~2~ -- 2.40 UV 24 h -- 2.40 UV 48 h -- 2.40   294          175, 191, 206
  Ox2              Unknown                        3% H~2~O~2~ -- 4.48 7.5% H~2~O~2~ -- 4.47 15% H~2~O~2~ -- 4.49   Inconclusive                                                                                                  
  Ox3              ![](fphar-07-00117-i006.jpg)   C~27~H~34~N~2~O~6~                                               3% H~2~O~2~ -- 5.72                                                                              471          177, 192, 206, 248
  Ox4              ![](fphar-07-00117-i007.jpg)   C~16~H~24~N~2~O~3~                                               3% H~2~O~2~ -- 6.37 7.5% H~2~O~2~ -- 6.29 UV 24 h -- 6.82                                        293          175, 206, 262
  Ox5              ![](fphar-07-00117-i008.jpg)   C~27~H~36~N~2~O~6~                                               3% H~2~O~2~ -- 7.75 7.5% H~2~O~2~ -- 7.68 15% H~2~O~2~ -- 7.76                                   485          177, 206, 262
  **Photolysis**                                                                                                                                                                                                                 
  xUV1             ![](fphar-07-00117-i009.jpg)   C~15~H~22~N~2~O~3~                                               UV 24 h -- 4.5                                                                                   279          175, 191, 206
  UV2              ![](fphar-07-00117-i010.jpg)   C~16~H~24~N~2~O~4~                                               UV 24 h -- 5.56 UV 48 h -- 5.58                                                                  309          204, 260, 278
  UV3              ![](fphar-07-00117-i011.jpg)   C~27~H~36~N~2~O~6~                                               UV 24 h -- 7.94                                                                                  485          146, 177, 204, 278
  UV4              ![](fphar-07-00117-i012.jpg)   C~26~H~34~N~2~O~5~                                               UV 24 h -- 11.6                                                                                  455          151, 177, 206, 262
                                                                                                                                                                                                                                 

###### 

Measured and calculated mass of molecular ion and fragmentation ion of degradation products, with calculated mass error.

  Monoisotopic mass   Measured   Theoretical   Mass error in m/z
  ------------------- ---------- ------------- -------------------
  IVA \[M+H\]^+^      469.2775   469.2697      -0.0078
                      262.1509   262.1438      -0.0071
                      177.1053   177.0910      -0.0143
  H1 \[M+H\]^+^       505.2908   505.3073      0.0165
                      280.1543   280.1684      0.0141
                      223.0965   223.1020      0.0055
                      177.0901   177.1003      0.0102
                      151.0754   151.0814      0.0060
  H2 \[M+H\]^+^       523.2590   523.2569      0.0021
                      284.1424   284.1412      0.0012
                      280.1684   280.1543      0.0141
                      223.1020   223.0965      0.0055
                      213.0758   213.0677      0.0081
                      177.1053   177.0901      0.0152
                      151.0814   151.0754      0.0060
  H3 \[M+H\]^+^       505.2482   505.2464      0.0018
                      262.1631   262.1438      0.0193
  N1 \[M+H\]^+^       487.2875   487.2803      -0.0072
                      280.1684   280.1543      -0.0141
                      177.1003   177.0901      -0.0102
  Ox1 \[M+H\]^+^      294.1384   294.1580      0.0196
  Ox3 \[M+H\]^+^      471.2718   471.2490      -0.0228
                      248.1322   248.1281      -0.0041
                      177.0951   177.0910      -0.0041
  Ox 4 \[M+H\]^+^     293.2008   293.1860      -0.0148
                      262.1570   262.1438      -0.0132
  Ox5 \[M+H\]^+^      485.2667   485.2646      -0.0021
                      262.1502   262.1438      -0.0064
                      177.0901   177.0910      0.0009
  UV1 \[M+H\]^+^      279.1682   279.1703      0.0021
  UV2 \[M+H\]^+^      309.1932   309.1809      -0.0123
                      278.1543   278.1387      -0.0156
  UV3 \[M+H\]^+^      485.2814   485.2646      -0.0168
                      278.1543   278.1387      -0.0156
                      177.1003   177.0901      -0.0102
  UV4 \[M+H\]^+^      455.2592   455.2540      -0.0052
                      262.1570   262.1438      -0.0132
                      177.1003   177.0901      -0.0102
                      151.0860   151.0754      -0.0106
                                               

The ketone group on the benzoazepine ring in compound **H1** has been oxidized to a carboxyl group (**Figure [5](#F5){ref-type="fig"}**). The characteristic peak m/z = 280 on the mass spectrum corresponding to the open azepine ring near the nitrogen, is observed for three of the four products of hydrolysis (**Figures [5](#F5){ref-type="fig"}**, **[6](#F6){ref-type="fig"}**, and **[8](#F8){ref-type="fig"}**). Water and HCl near the benzocyclobutene in compounds **H1** and **H2** are attached without a covalent bond, a kind of adducts may be formed. The situation is similar for the product **H3**, except that here the ring benzoazepine is intact (no peak of m/z = 280) and the fragmentation spectrum of MS/MS proved there is impossible sufficiently formation of the HCl adduct closely to the molecule (**Figure [7](#F7){ref-type="fig"}**). Compound **N1**, as another product of ivabradine hydrolysis (**Figure [8](#F8){ref-type="fig"}**) differs only by oxidized carboxyl group on the benzoazepine ring near the nitrogen, what is observed as opening of the ring.

Due to the high level of noise and discrepancies in the resulting MS/MS spectrum of compound **Ox2**, its identification is impossible, but due to repetition of its occurrence, there is importance to place attention on that compound in stability testing of ivabradine.

Limitations of the MS-Q-TOF method used for identification of degradation products of **IVA** did not allow for a clear determination of the attachment site of the hydroxyl group in compound **Ox3**, but it is possible the covalent bond forms between nitrogen atoms in the molecule.

Compounds **Ox4** and **Ox1** have similar masses (m/z 293.20 and 294.1388, respectively) as well as the fragmentation spectra. Differences are in the presence of diverse substituents near the nitrogen atom in the molecule chain, a methyl group in **Ox4** (**Figure [9](#F9){ref-type="fig"}**), and oxygen in **Ox1**. Oxygen is coupled to the nitrogen atom also in case of compound **Ox5**, where it forms *N*-oxide bond.

Compound **UV1** (**Figure [10](#F10){ref-type="fig"}**) is the degradation product of the smallest identified molecular weight identified of **IVA** (m/z = 279.1725). For compounds **UV2** and **UV3** it is impossible to predict its structures, but the data suggest that OH group is joined in the region of benzoazepine ring. Compound UV4 is varies from ivabradine by the lack of the methyl group on the nitrogen atom (**Figure [11](#F11){ref-type="fig"}**). It is proved, that compound **UV4** is a metabolite of ivabradine produced by cytochrome P450.

ADME/Tox Screening for Degradation Products
-------------------------------------------

The calculation of pharmacological and toxicological properties could be done only for six ivabradine degradation products, since its chemical structures managed to establish for obtained data. In other degradation products we proposed the most probable chemical structures only on the basis of MS/MS analysis.

The pharmacological effect of ivabradine is associated with blocking of HCN4 channels ([@B24]). Therefore, in order to make comparative analysis calculations were also done for ivabradine, even though the drug is introduced into clinical practice. The *in silico* calculations made for ivabradine and selected degradation products demonstrated high probability of HCN4 channel inhibition for **Ox4**, **Ox5**, **UV1**, and **UV4**, which may indicate a certain pharmacological action of these products (**Table [4](#T4){ref-type="table"}**). For a compound **UV4** calculated value of inhibition is very high (0.94) and only slightly lower than calculated value for the ivabradine (0.96). It is known that compound **UV4** is a metabolite of ivabradine with proved ability to inhibit HCN4 channels. Other studies have shown that it is much weaker inhibitor than ivabradine ([@B5]).

###### 

ADME/Tox calculations for ivabradine and selected degradation products.

                                                                                        \[19\]    \[18\]                     \[18\]                     \[18\]                    \[18\]
  ----- ----- ------------------------------------------------------------------------- --------- -------------------------- -------------------------- ------------------------- ----------------------------
  IVA   468   CN(CCCN1CCc2cc (c(cc2CC1 = O)OC)OC) CC3Cc4c3cc(c (c4)OC)OC                0.96^b^   Inhibitor (57.0%^c^)       Inhibitor (74.0%^c^)       3.18 Log unit ± 0.38^d^   3.51 -log(mol/L) ± 0.70^d^
  N1    487   CN(CCCNCCc1cc (c(cc1CC( = O)O) OC)OC)CC2Cc3c2cc (c(c3)OC)OC               0.28^b^   Non-inhibitor (65.0%^c^)   Non-inhibitor (84.0%^c^)   2.71 Log unit ± 0.38^d^   2.39 -log(mol/L) ± 0.70^d^
  Ox1   294   COc1cc2c(cc1OC) CC( = O)N(CC2) CCCN\[O-\]                                 0.40^b^   Non-inhibitor (84.0%^c^)   Non-inhibitor (86.0%^c^)   0.57 Log unit ± 0.74^d^   0.98 -log(mol/L) ± 0.70^d^
  Ox4   293   CNCCCN1CCc 2cc(c(cc2CC1 = O)OC)OC                                         0.82^b^   Non-inhibitor (69.0%^c^)   Non-inhibitor (89.0%^c^)   1.23 Log unit ± 0.38^d^   1.36 -log(mol/L) ± 0.70^d^
  Ox5   485   C\[N+\](CCCN1CC c2cc(c(cc2CC1 = O) OC)OC)(CC3Cc4c3cc (c(c4)OC)OC)\[O-\]   0.77^b^   Non-inhibitor (79.0%^c^)   Inhibitor (62.0%^c^)       1.26 Log unit ± 0.74^d^   2.39 -log(mol/L) ± 0.70^d^
  UV1   279   COc1cc2c (cc1OC)CC( = O) N(CC2)CCCN                                       0.79^b^   Non-inhibitor (85.0%^c^)   Non-inhibitor (87.0%^c^)   0.42 Log unit ± 0.38^d^   0.9 -log(mol/L) ± 0.70^d^
  UV4   455   COc1cc2c(cc1OC) CC( = O)N(CC2) CCCNCC3Cc4c3cc (c(c4)OC)OC                 0.94^b^   Non-inhibitor (59.0%^c^)   Inhibitor (76.0%^c^)       2.43 Log unit ± 0.38^d^   3.03 -log(mol/L) ± 0.70^d^
                                                                                                                                                                                  

a

Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4;

b

probability;

c

accuracy;

d

within a confidence interval of 66%.

Ivabradine and its degradation products showed no mutagenicity in the Ames test. It was also shown, that no inhibition of cytochromes: CYP2C9, CYP2C19, and CYP1A2 (data calculated but not included in **Table [4](#T4){ref-type="table"}**) occurs for all products of degradation and ivabradine itself. According to obtained calculations only ivabradine inhibits CYP2D6. Some authors refer only to the inhibition of CYP3A4 by **IVA** ([@B5]; [@B24]), which is confirmed by our calculations. Compound **UV4,** which has lower pharmacological activity than ivabradine, demonstrated inhibition of cytochrome, the same as compound **Ox5**.

The values of log P and aqueous solubility, allow to divide identified degradation products into three groups. Degradation products of ivabradine - compounds **UV4** and **N1** have slightly reduced values of log P and solubility in comparison to **IVA**. In the case of degradation products **Ox4** and **Ox5,** significant reduction of lipophilicity is observed. A strong decrease in lipophilicity and aqueous solubility occurred in the case of compounds **Ox1** and **UV1**. Significant reduction of the log P values can be explained by an aromatic ring being highly lipophilic moiety.

Conclusion
==========

Stress testing of ivabradine was presented with successful identification and characterization of its degradation products. The obtained compounds showed no mutagenic effects in performed *in silico* models, in which toxicity and the effect on cytochromes seems to be small. Another important aspect was, that their lower water solubility and lipophilicity in comparison to ivabradine, may influence their bioavailability after oral administration. Above all, lower pharmacological activity of degradation products was proven in calculated value of channel inhibition HCN4. There was also computationally confirmed pharmacological activity of compound **UV4**.
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